Ketone Ester Treats Angelman Syndrome Seizures in Mouse Model

Added:

Translational Barriers and Symptom Management vs. Disease-Modifying Gene Therapies

While the use of ketone esters shows promise in mouse models, significant hurdles remain regarding human translation and therapeutic scope. First, preclinical success in rodent models of Angelman syndrome frequently fails to translate into clinical efficacy in humans due to key physiological and metabolic differences. Second, exogenous ketone therapies are highly challenging to maintain in pediatric populations due to poor palatability, gastrointestinal side effects, and long-term compliance issues. Most importantly, ketone esters serve as a symptomatic intervention rather than a cure. They address downstream symptoms like seizures and motor deficits but do not correct the underlying genetic root of Angelman syndrome—the loss of maternal UBE3A gene expression. In contrast, emerging genetic therapies, such as antisense oligonucleotides (ASOs) and gene reinstatement therapies, aim to restore UBE3A expression directly in the brain, offering a potentially disease-modifying or curative approach that metabolic therapies cannot match.

Understanding the genetic and clinical profile of Angelman syndrome, including its association with the maternal UBE3A gene and symptoms like cognitive deficits, motor impairment, and epilepsy.
Basic concepts of brain metabolism, specifically how the brain utilizes alternative energy sources like ketone bodies (e.g., beta-hydroxybutyrate) when glucose is scarce.
The neurophysiology of seizures, focusing on the imbalance between excitatory (glutamatergic) and inhibitory (GABAergic) signaling in the central nervous system.
The role and limitations of preclinical animal models (specifically transgenic mouse models) in biomedical research and drug discovery.
The translational pathway and regulatory challenges involved in moving a successful preclinical treatment (like ketone esters) from mouse models to human clinical trials.
The specific molecular mechanisms through which exogenous ketones exert anticonvulsant and neuroprotective effects (e.g., ATP production, mitochondrial function, and epigenetic modifications).
A comparative study of dietary interventions (like the ketogenic diet) versus exogenous supplementation (ketone esters/salts) in managing neurological disorders.
Other cutting-edge therapeutic strategies for Angelman syndrome, such as gene therapy, CRISPR-based activation of the paternal UBE3A gene, and antisense oligonucleotides (ASOs).
1.3K views9likes22:43@epigenixfoundation5302Original Release: 2016-07-15

Ketone ester supplementation in Angelman syndrome mouse models improves multiple disease phenotypes including motor coordination, learning and memory, and seizure threshold, while increasing the GABA/glutamate ratio in the hippocampus, suggesting a potential therapeutic approach for this genetic disorder.